💧 Medication-Induced Dry Mouth Simulator

Normal Salivary Gland Secretion

Healthy acinar cells respond fully to parasympathetic acetylcholine signals.

• 0.3–0.4: Unstimulated flow rate (mL/min resting baseline)
• 1–2: Stimulated flow rate (mL/min while eating)
• 0.5–1.5 L: Daily saliva volume (produced per day)
• M3: Key receptor subtype (primary acinar muscarinic receptor)

Parasympathetic control

Vagal nerve fibers release acetylcholine onto acinar cells.

M3 receptor signaling

ACh binds M3 receptors, triggering calcium-driven secretion.

Healthy fluid output

Water and electrolytes flow freely into salivary ducts.

Anticholinergic Drug Exposure

Anticholinergic drugs directly block muscarinic receptors on gland cells.

• Anticholinergics: Drug class (atropine-like agents)
• High: Receptor affinity (competitive antagonism)
• 80%+: Xerostomia prevalence (of anticholinergic users)
• Minutes: Onset of dry mouth (after dosing)

Competitive receptor blockade

Drug molecules outcompete acetylcholine at M3 receptors.

Reduced fluid secretion

Blocked receptors halt calcium signaling and water flow.

Common offending drugs

Oxybutynin, atropine, and scopolamine are classic culprits.

Antihistamine-Induced Receptor Suppression

Sedating antihistamines add off-target anticholinergic receptor blockade.

• 1st-gen antihistamines: Drug class (diphenhydramine-like agents)
• Off-target: Added mechanism (anticholinergic side effect)
• Additive: Combined burden (stacks with other drugs)
• Very common: OTC availability (allergy and sleep aids)

Off-target receptor activity

Sedating antihistamines also block muscarinic receptors.

Layered receptor occupancy

Second drug class adds to existing blockade.

Everyday exposure risk

Common allergy and sleep medications worsen dry mouth.

Antidepressant-Related Xerostomia

Tricyclic and SSRI antidepressants further suppress salivary secretion.

• TCAs & SSRIs: Drug class (amitriptyline, sertraline)
• Muscarinic + serotonergic: Mechanism (dual pathway effect)
• Long-term: Chronic use impact (continuous suppression)
• Millions: Patients affected (on long-term therapy)

Tricyclic receptor blockade

TCAs bind muscarinic receptors with strong affinity.

SSRIs and dry mouth

SSRIs cause milder but persistent secretion suppression.

Chronic therapy consequence

Long-term antidepressant use sustains reduced saliva output.

Polypharmacy and Cumulative Xerostomia

Combined drug classes produce severe, compounding dry mouth.

• 5+: Drugs per elderly patient (common polypharmacy threshold)
• Sharply higher: Xerostomia risk (with each added drug)
• <0.1: Severe flow reduction (mL/min near-total blockade)
• Caries, infection: Complications (oral health decline)

Cumulative receptor saturation

Multiple drug classes block nearly all receptors.

Compounding anticholinergic burden

Each added medication multiplies dry mouth severity.

Clinical consequences

Severe xerostomia raises caries, infection, and swallowing risk.